Phase I and pharmacokinetic evaluation of the combination of orally administered docetaxel and cyclosporin A in tumor-bearing dogs

American Journal of Veterinary Research

Volumn 67, Issue 6, 2006, Pages 1057-1062

  McEntee, Margaret C ^a   Rassnick, Kenneth M ^a   Lewis, Lionel D ^b   Zgola, Marsha M ^a   Beaulieu, Bernard B ^b   Balkman, Cheryl E ^a   Page, Rodney L ^a  

^a Department of Obstetrics Gynecology   (United States)

^b DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; DOCETAXEL;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; BLOOD ANALYSIS; BONE MARROW SUPPRESSION; CANCER RESISTANCE; CANCER STAGING; CONTROLLED STUDY; DOG DISEASE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG ELIMINATION; DRUG HYPERSENSITIVITY; FEMALE; GASTROINTESTINAL TOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTOXICATION; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; NONHUMAN; OPEN STUDY; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; CYCLOSPORINE; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; MALE; NEOPLASMS; TAXOIDS;

ANIMALIA; CANIS FAMILIARIS;

EID: 33745675665     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.67.6.1057     Document Type: Article

References (27)

1. Bissery MC, Nohynek G, Sanderink GJ, et al. Docetaxel (taxotere®): a review of preclinical and clinical experience. Part 1: preclinical experience. Anticancer Drugs 1995;6:339-368.
2. Masini E, Planchenault, Pezziardi F. et al. Histamine-releasing properties of polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions 1985;16:470-477.
3. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
4. van Asperen J, van Tellingen O, Beijnen JH. The pharmacological role of p-glycoprotein in the intestinal epithelium. Pharmacol Res 1998;37:429-435.
5. van Zuylen L, Verweij J, Nooter K, et al. Role of intestinal p-glycoprotein in the plasma and fecal disposition of docetaxel in humans. Clin Cancer Res 2000;6:2598-2603.
6. Schellens JHM, Malingre MM, Kruijtzer CMF, et al. Modulation of oral bioavailability of anticancer drugs: from mouse to man. Eur J Pharm Sci 2000;12:103-110.
7. Malingre MM, Richel DJ, Beijnen JH, et al. Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel. J Clin Oncol 2001;19:1160-1166.
8. McEntee M, Silverman JA, Rassnick K, et al. Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol 2003;1:105-112.
9. World Health Organization. Update 2001: recommendations for grading of acute and subacute toxicities. Available at: www.fda.gov/cder/cancer/ toxicityframe.htm. Accessed November 2005.
10. 2 dose in combination with granulocyte-colony stimulating factor in patients with ovarian cancer. Cancer Chemother Pharmacol 1993;33:48-52.
11. Chesne C, Guyomard C, Guillouzo A, et al. Metabolism of meloxicam in human liver involves cytochromes P4502C9 and 3A4. Xenobiotica 1998;28:1-13.
12. Sparreboom A, de Jonge MJA, Verweij J. The use of oral cytotoxic and cytostatic drugs in cancer treatment. Eur J Cancer 2002;38:18-22.
13. Milas L. Docetaxel/radiation combinations: rationale and preclinical findings. Clin Lung Cancer 2002;3(suppl 2):S29-S36.
14. Calais G, Bardet E, Sire C, et al. Radiotherapy with concomitant weekly docetaxel for stages III/IV oropharynx carcinoma. Results of the 98-02 gortec phase II trial. IntJ Radiat Oncol Biol Phys 2004;58:161-166.
15. Damiani D, Michieli M, Ermacora A, et al. Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia. Leukemia 1998;12:1236-1240.
16. Li Z, Ibrahim NK, Wathen JK, et al. Colitis in patients with breast carcinoma treated with taxane-based chemotherapy. Cancer 2004;101:1508-1513.
17. Stemmler HJ, Kenngott S, Diepolder H, et al. Gastrointestinal toxicity associated with weekly docetaxel treatment. Ann Oncol 2002;13:978-981.
18. ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol 2005;23:1070-1077.
19. Engels FK, Sparreboom A, Mathot RAA, et al. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review. Br J Cancer 2005;93:173-177.
20. Puisset F, Chatelut E, Dalenc E et al. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 2004;54:265-272.
21. Yamamoto N, Tamura T, Murakarm H, et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005;23:1061-1069.
22. Aapro M, Bruno R. Early clinical studies with docetaxel. Eur J Cancer 1995;31A(suppl 4):7-10.
23. Malingre MM, Beijnen JH, Rosing H, et al. The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel. Anticancer Drugs 2001;12:351-358.
24. Puhlmann U, Ziemann C, Ruedell G, et al. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther 2005;312:346-354.
25. Ziemann C, Schafer D, Rudell G, et al. The cyclooxygenase system participates in functional mdr1b overexpression in primary rat hepatocyte cultures. Hepatology 2002;35:579-588.
26. Isogai R, Kawada A, Aragane Y, et al. Successful treatment of pulmonary metastasis and local recurrence of angiosarcoma with docetaxel. J Dermatol 2004;31:335-341.
27. Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005;104:361-366.